Revvity Omics Sweden
Revvity Omics Sweden is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants with Genetically Diagnosed Spinal Muscular Atrophy
Sponsor Biogen Idec Research Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam
Sponsor Biogen Idec Research Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, Multi-Center, Open Label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
Sponsor Ns Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
An Operationally Seamless, Randomized Phase 2/3 Study Consisting of a Phase 2 Single Blind, Dose-Evaluation Phase and a Phase 3 Double-Blind, Placebo-controlled Phase to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Revvity Omics Sweden?
The 2026-10-09 snapshot links Revvity Omics Sweden to 4 distinct CTIS trials. Recorded services include Laboratory services, genetic testing for screening and eligibility confirmation, Genomic screening services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Revvity Omics Sweden?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Neurology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Revvity Omics Sweden conducted?
The linked trials record locations in 15 countries, including Italy, Germany, France, Poland, Spain. These are trial locations, not confirmed office locations or countries where Revvity Omics Sweden delivered services.
What can this page tell me about Revvity Omics Sweden's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Revvity Omics Sweden. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Revvity Omics Sweden AB